DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Gemigliptin

Generic Name: Gemigliptin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉F_₈N_₅O_₂

CAS Number: 911637-19-9

Unique Ingredient Identifier: 5DHU18M5D6

Overview

Gemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

Background

Gemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

Indication

No indication information available.

Associated Conditions

Type 2 Diabetes Mellitus

Clinical Trials

Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes

Phase 4

Recruiting

Posted: 2022/12/23

Sponsor:Seoul National Unive...

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Phase 4

Recruiting

Posted: 2022/01/18

Sponsor:

Wonju Severance Chri...

Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

Phase 1

Posted: 2021/11/03

Sponsor:

LG Chem

Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification

Not Applicable

Completed

Posted: 2021/01/12

Sponsor:Bangkok Metropolitan...

Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.

Phase 1

Completed

Posted: 2020/03/23

Sponsor:

LG Chem

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy